Stay updated on SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.

Latest updates to the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe study record for the SWIPE phase II trial of maintenance pembrolizumab in metastatic non-small cell lung cancer is displayed, with details on the study plan, participants, outcomes, investigators, and associated documents.SummaryDifference49%

- Check19 days agoChange DetectedThe ClinicalTrials.gov footer revision label updates from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.SummaryDifference1%

- Check33 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe SWIPE study page now presents a 403 error page, replacing the previously visible trial details and identifiers with a generic error screen, effectively hiding the study information from the public view.SummaryDifference18%

Stay in the know with updates to SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.